Chronic Granulocytic Leukemia (CGL) occurs due to chromosomal translocation (9;22) known as Philadelphia chromosome. p210 BCR-ABL1 oncogenes are classified into b2a2 and b3a2 transcripts which possibly lead to different clinical manifestations and response to therapy. This study was aimed to prove that there is a difference of bone marrow features and BCR-ABL between remissive and resistant CGL after Tyrosine Kinase Inhibitor (TKI) therapy. This research was an observational study with a cross-sectional design carried out at Ulin Hospital Banjarmasin on 32 subjects. BCR ABL was detected by using PCR and bone marrow features were assessed by using bone marrow aspiration technique. The difference of bone marrow features and BCR-ABL variants was analyzed by using T-test (p < 0.005) and Chi-Square (p < 0.005), respectively. There was a difference of BCR-ABL variants with p=0.091 and characterized by M:E ratio (p=0.124), myeloblast count (p=0.063), and eosinophil count (p=0.055). In addition, there was a difference of bone marrow cellularity (p=0.000) and basophil count (p=0.016) between remissive CGL and resistant CGL patients. There was no difference of BCR ABL variants, myeloblast count and eosinophil count between remissive CGL and resistant CGL patients. However, there was different of bone marrow cellularity and basophil count between remissive CGL and resistant CGL patients.
Oxidative stress in β-TM (beta-thalassemia major) patients is associated with increased of malondialdehyde (MDA) level and also decreased of superoxide dismutase (SOD) level. Deferiprone and deferasirox, which are used for the treatment of iron overload, exhibit antioxidant potential. However, various clinical studies have shown an increase in creatinine levels in pediatric patients receiving oral iron chelator. There was limited study assessed oxidative stress and impact of β-TM on the renal function, especially in children that growing up with β-TM and receiving iron chelator. Therefore, the aim of the study is to investigate renal function and oxidative stress between β-TM patients at Ulin Hospital Banjarmasin who received deferasirox and deferiprone. Ninety β-TM patients (aged 2-≤18 years) with regular iron chelators (deferiprone or deferasirox) use at Ulin Hospital between October-December 2020, were included in this cross-sectional study. Laboratory examinations included complete peripheral blood count, serum ferritin, urea, creatinine, MDA and SOD. Statistical analysis was used to compare all parameters between two groups.There was no significant difference in the levels of MDA (p= 0.663), SOD (p= 0.102), urea (p= 0.597), creatinine (p= 0.067) and glomerular filtration rate (p= 0.792) between the two groups. In this study, 9 patients had decreased GFR, of which 3 patients (33.3%) were taking DFX. Thus, 13.6% of DFX users (3 of 22 patients) and 8.8% of DFP users (6 of 68 patients) had decreased renal function. In general, the mean glomerular filtration rate (GFR) of the patients in this study ranged from 126.74± 32.71ml/kg/min/1.73m2. For conclusion, deferiprone and deferasirox had no significant difference in terms of protection against oxidative stress. However, the decline in renal function occurred slightly higher in deferasirox users. Early recognition will be an important key to prevent renal complication
One of the most widely used anticoagulants for a complete blood count is ethylenediaminetetraacetic acid (EDTA). Pseudothrombocytopenia (PTCP) may be caused by EDTA, this condition may lead to inappropriate diagnosis and treatment. We report a 25-year-old female with unspecific headache and joint pain with very low platelet count since 1 month before hospital admission. She was diagnosed with Dengue fever infection and got some platelet transfusion from the previous secondary hospital. She was carried out for a blood test with another anticoagulant (sodium citrate) and bone marrow aspiration. The results showed that she had normal platelet count and bone marrow cellularity. When a patient was identified with thrombocytopenia without any bleeding manifestation, hematology disease, and family history, PTCP should be taken into consideration to prevent unnecessary intervention. Keywords: platelet, pseudothrombocytopenia, ethylenediaminetetraacetic acid, Dengue fever
Background: Acute leukemia is a malignant disease involving hematopoietic tissue, characterized by abnormal blood cells in bone marrow or called blast cells. The most common complications of acute leukemia is bleeding. A high percentage of blasts has been reported to increase the risk of bleeding in acute leukemia. Preliminary study was needed to investigate relationship between blast cells count and bleeding incidence in acute leukemia. Methods: Crosssectional study with observasional analytic in 18 adult subjects was conducted from November 2019 to March 2020 in Ulin Hospital Banjarmasin South Kalimantan. The data were taken from medical records of acute leukemia patients who met inclusion and exclusion criterias. Data analysis was using Fisher’s exact test. Results: There were 7 men and 11 women in this study. Blast cells count in peripheral with cut off <50% was 9 (50%) and ≥50% was 9 (50%). It was same for blast cells count in bone marrow. Both of women and men mostly have bleeding in acute leukemia, and bleeding incidence in women is higher than men. Bleeding condition was happened both in peripheral and bone marrow blast cells count with cut of <50% and ≥50%. Significancy of relationship between blast cells count and bleeding incidence was 0.637. Conclusion: There is no significant between blast cells count and the bleeding incidence in acute leukemia. Another parameters that could be influenced bleeding inceidence need to be investigate in acute leukemia.
Introduction. Neonatal sepsis is the leading cause of death in newborns. The initial symptoms of sepsis are usually unclear, the clinician often judge these conditions based on risk factor and clinical examination. Blood culture is one of the parameters to be checked but the result takes time. It is also usually come with a positive result of 10 - 60% only. Another biologic marker such as hematologic one is used to evaluate the sepsis because it is considered faster enough. The aim of study is to evaluate the significant changes in biologic marker during neonatal sepsis with positive risk factors. Methods. This was a cross sectional study. All <72 hours old’s neonates with positive risk factors, neonates who admitted in July to September 2015 in the Neonatal Intensive Care Unit (NICU), and clinically suspected of sepsis were included. Laboratory results of each case were recorded. The eight variables of biologic hematologic parameters of the neonates (hemoglobin, leukocytes, platelet counts, IT (immature to total neutrophil) ratio, IM (immature to mature neutrophil) ratio, polymorphonuclear, immature polymorphonuclear, and hematological scoring (HSS)); one variable of C-reactive protein, and one variable culture result were assessed. Each variable will be compared based on culture result using independent T-test of SPSS. Results and Discussion. Thirty-six samples were found which consist of twenty-nine negative and seven positive sample of culture results. All statistical variable’s results weren’t significant (p >0,05). These results showed there is no significant changes to these variables even if there are any risk factors within the neonates. Higher or lower value of these variable did also not prove whether the culture is positive. Conclusion. No significant changes in biologic marker during neonatal sepsis with positive risk factors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.